Skip to main content
VISEN Pharmaceuticals logo

VISEN Pharmaceuticals — Investor Relations & Filings

Ticker · 2561 ISIN · KYG9363A1003 LEI · 254900OJ8HIP6GRV1044 HKEX Manufacturing
Open in API
Filings indexed 67 across all filing types
Latest filing 2025-03-12 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 2561

About VISEN Pharmaceuticals

http://www.visenpharma.com

VISEN Pharmaceuticals is an innovative biopharmaceutical company focused on the development and commercialization of paradigm-shifting therapies for endocrine diseases. The company is committed to addressing unmet medical needs within the Greater China market by providing innovative treatments and compassionate patient care. VISEN's core strategy involves leveraging advanced drug delivery platforms, which utilize prodrugs connected to carrier molecules via a linker structure. This technology enables the controlled, slow release of the unmodified prototype drug, ensuring sustained therapeutic action while the linker and carrier are safely excreted. VISEN serves as a key strategic partner for global biopharma companies seeking to commercialize high-quality endocrine assets in the region.

Recent filings

Filing Released Lang Actions
GLOBAL OFFERING
Regulatory Filings
2025-03-12 English
GLOBAL OFFERING
Capital/Financing Update Classification · 84% confidence The document is a detailed announcement of the company’s Global Offering (IPO) on the Hong Kong Stock Exchange, including share allocations, offering size, price range, underwriting arrangements, and application procedures. This is an announcement of a capital raise and change in the company’s capital structure rather than an annual or interim financial report, management discourse, or regulatory filing of voting results, governance, or legal proceedings. It fits Squarely into a financing update category.
2025-03-12 English
PHIP (1st submission)
Share Issue/Capital Change Classification · 76% confidence The document is the detailed Post-Hearing Information Pack (PHIP) for VISEN Pharmaceuticals’ proposed listing and public share offering in Hong Kong. It constitutes the draft prospectus and supplementary listing document covering the share issuance, underwriting arrangements, timetable, risk factors, financial information, and corporate structure. This is not an annual or interim report, earnings release, or management call transcript, but directly concerns a new share issue and capital change. The most fitting category is Share Issue/Capital Change (SHA).
2025-02-09 English
PHIP (1st submission)
Audit Report / Information Classification · 95% confidence The document is a 'PHIP' (Post-Hearing Information Proof) filing from the Hong Kong Stock Exchange (HKEX). A PHIP is a preliminary document published by a company preparing for an Initial Public Offering (IPO). It contains detailed sections such as 'Business', 'Financial Information', and 'Accountants' Report', which are characteristic of a prospectus. Since the document is a listing-related disclosure document rather than a periodic financial report or a simple announcement, it falls under the category of Regulatory Filings (RNS) as the most appropriate fallback for IPO-related documentation in this schema. FY 2024
2025-02-09 English
OC Announcement - Appointment
Regulatory Filings Classification · 95% confidence The document is an announcement made by VISEN Pharmaceuticals pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. It contains disclaimers about the nature of the announcement, stating it is not a prospectus or an offer to sell securities, and emphasizes that no investment decision should be based on this announcement. It mentions the appointment of overall coordinators for a potential offering and states that further announcements will be made as required. The document does not contain financial statements, detailed financial data, or management discussion and analysis. It is primarily an informational announcement related to a potential securities offering and listing application, not the offering document itself or a financial report. The length is 7,822 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best as a Regulatory Filing (RNS), which is a general regulatory announcement that does not fit into other specific categories.
2024-09-26 English
Application Proof (1st submission)
Audit Report / Information Classification · 95% confidence The document is an 'Application Proof' for VISEN Pharmaceuticals, which is a standard term used in the Hong Kong Stock Exchange (HKEX) for a preliminary prospectus filed during an Initial Public Offering (IPO) process. The document contains links to sections typical of a prospectus, such as 'Industry Overview', 'Business', 'Financial Information', and 'Accountants' Report'. Since the filing category 'POS' (Transaction in Own Shares) or 'SHA' (Share Issue) does not capture the nature of an IPO prospectus, and there is no specific 'IPO' category provided in the list, 'RNS' (Regulatory Filings) serves as the appropriate fallback for this type of regulatory disclosure. FY 2023
2024-09-26 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.